Global 500

Rank
255
Previous: 254 Next: 256

Merck

Pharmaceutical Production Inside Merck KGaA Health Care Laboratory
An employee monitors Euthyrox hypothyroid treatment tablets as they pass through a blister pack packaging machine inside Merck KGaA's pharmaceutical laboratories at the company's headquarters in Darmstadt, Germany, on Thursday, Nov. 3, 2016. Merck and Idemitsu Kosan Co Ltd. today signed an agreement to allow each party to use the other's organic light-emitting diode (OLED) material-related patents in certain areas. Photographer: Martin Leissl/Bloomberg via Getty ImagesMartin Leissl — Bloomberg via Getty Images
  • Previous Rank
    246
  • Revenues ($M)
    39807
  • Revenue Percent Change
    0.8
  • Profits ($M)
    3920
  • Profits Percent Change
    -11.8
  • Assets ($M)
    95377
  • Employees
    68000

Merck brought in $39.8 billion in 2016 global sales. The U.S. drug giant's wide-ranging portfolio was crucial to that haul--but the company's next-generation cancer immunotherapy treatment, Keytruda, is what really set it apart last year. The therapy bested rival Bristol-Myers Squibb's competing Opdivo in the critical lung cancer space, according to clinical trial data, making it (and Merck) one of the most formidable players in the latest strike on cancer.

Company Information

CEOKenneth C. Frazier
SectorHealth Care
IndustryPharmaceuticals
HQ LocationKenilworth, NJ
Websitewww.merck.com
Years on Global 500 List23
Employees68,000

Key Financials (Last Fiscal Year)

Revenues ($M)$39,807
Profits ($M)$3,920
Assets ($M)$95,377
Total Stockholder Equity ($M)$40,088

Profit Ratios

Profit as % of Revenues9.8%
Profits as % of Assets4.1%
Profits as % of Stockholder Equity9.8%